Orrick has advised San Francisco-based biopharmaceutical company Cortexyme on its $75 million initial public offering of 4.412 million shares of common stock. The offering priced at $17 per share and began trading today on the Nasdaq Global Select Market under the ticker symbol “CRTX.”
In addition, Cortexyme has granted the underwriters a 30-day option to purchase up to 661,800 additional shares of common stock. The offering is expected to close on May 13, 2019, subject to customary closing conditions.
BofA Merrill Lynch and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the proposed offering. Canaccord Genuity LLC and JMP Securities LLC are acting as co-managers.
The team advising Cortexyme was led by Scott Iyama and included Andy Thorpe, Pete Lamb, Vinella Sido, Brigid McCurdy, Laura Bloxham, Christine McCarthy, Katherine Hogan, Will Peifer, Mark Nguyen, Taylor Stenberg, Valerie Guillard Hein, Sheila Maguire, Daniel Yost, Eric Wall, Stephen Lessard and Jamie Herkins.